可溶性程序性死亡受体配体1作为肺癌的预测生物标志物：一项系统评价和荟萃分析。
Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
作者信息
Cheng Yang, Wang Chong, Wang Yan, Dai Li
机构信息
Department of Respiratory & Critical Care Medicine, Beijing Jishuitan Hospital, The Fourth Medical College of Peking University, Beijing 100035, China.
Minimally Invasive Treatment Center, Beijing Chest Hospital, Beijing 101149, China.
出版信息
Future Oncol. 2022 Jan;18(2):261-273. doi: 10.2217/fon-2021-0641. Epub 2021 Dec 7.
We performed a meta-analysis to evaluate the association between soluble PD-L1 (sPD-L1) and survival outcomes and treatment response in lung cancer. Eligible studies were obtained by searching PubMed, EMBASE and Web of Science. Pooled effect estimates were calculated for overall survival (OS), progression-free survival (PFS) and objective response rate (ORR). Twelve eligible studies with 1188 lung cancer patients were included. High sPD-L1 was significantly associated with worse OS (hazard ratio [HR] = 2.20; 95% CI: 1.59-3.05; p < 0.001) and PFS (HR = 2.42; 95% CI: 1.72-3.42; p < 0.001) in patients treated with immune checkpoint inhibitors (ICIs). Meanwhile, high sPD-L1 predicted worse OS (HR = 1.60; 95% CI: 1.31-1.96; p < 0.001) and lower ORR (odds ratio = 0.52; 95% CI: 0.35-0.80; p = 0.002) in patients treated with non-ICI therapies. sPD-L1 is a potential predictive biomarker of lung cancer.
我们进行了一项荟萃分析，以评估可溶性程序性死亡配体1（sPD-L1）与肺癌患者生存结局及治疗反应之间的关联。通过检索PubMed、EMBASE和Web of Science获取符合条件的研究。计算总生存期（OS）、无进展生存期（PFS）和客观缓解率（ORR）的合并效应估计值。纳入了12项符合条件的研究，共1188例肺癌患者。在接受免疫检查点抑制剂（ICI）治疗的患者中，高sPD-L1水平与较差的OS（风险比[HR]=2.20；95%置信区间：1.59-3.05；p<0.001）和PFS（HR=2.42；95%置信区间：1.72-3.42；p<0.001）显著相关。同时，在接受非ICI治疗的患者中，高sPD-L1水平预示着较差的OS（HR=1.60；95%置信区间：1.31-1.96；p<0.001）和较低的ORR（优势比=0.52；95%置信区间：0.35-0.80；p=0.002）。sPD-L1是肺癌的一种潜在预测生物标志物。
Zotero 插件